MALMÖ, SWEDEN and RESEARCH TRIANGLE PARK, NC — JANUARY 7, 2020 — Trialbee, a world-leading technology provider in patient matching and engagement, today announced the company has experienced significant momentum as the demand for patient-centric technology solutions for global clinical trials continues to grow across multiple markets.
“As the only recruitment company able to source patients across electronic health records, claims data and targeted digital outreach, we have experienced remarkable momentum in 2019,” said Lollo Eriksson, CEO of Trialbee. “We attribute this growth to continued operational innovation and the key strategic partnerships we have established in 2019. Our commitment to delivering tailored solutions to our customers have enabled Trialbee to become an embedded partner with some of the world’s largest pharmaceutical companies, and our retention services have allowed us to establish long-term patient engagement projects particularly within the medical device space. We look forward to continuing this trajectory in the coming year.”
2019 milestones include:
- Significantly expanded customer traction and diversity with multiple new projects from Pharma, Biotech, CRO and the Medical Device industry.
- Became an embedded operational service partner for early and late phase clinical development with one of the world’s largest pharmaceutical companies, with active projects across multiple business unites and therapeutic areas.
- Launched two multi-year patient engagement projects for a leading medical device company.
- Added several dedicated leaders including experienced life sciences executive and digital health advisor Richard Thomas to the Board of Directors to provide key strategic, advisory and operational industry expertise.
Additionally, Trialbee established a strategic partnership with a leading global health research network in 2019, enabling data-driven digital solutions to accelerate patient-centric clinical trials by harnessing the power of real-world evidence (RWE) and real-time analytics to optimize protocol design, site selection, and patient recruitment and retention. This partnership allows the expansion into the oncology market/research/trials, which represents 40% of industry clinical development spending and close to 20% market share of pharma sale, as well as to the orphan drug trials, a market that is estimated to grow to more than $200B by 2022.
Trialbee is the first and only global patient recruitment and engagement company with integrated patient sourcing from claims data, electronic health records data and digital outreach to the general public. The expanded capabilites enables Trialbee to also provide services such as patient feasibility, principal investigator identification and observational research.
“2019 was a record year for Trialbee and the increase in repeat business demonstrates the level of trust and confidence we continue to build with our customers,” said Eriksson. “The volume of trials needed for developing new interventions to drive value-based health care is immense and steadily growing YoY. As our trends indicate, 2020 is set to be another record year for Trialbee.”
Trialbee is a world leading technology provider in patient matching and engagement, empowering patients to participate in clinical trials as a care option. Founded in 2010, Trialbee has continuously innovated patient-centric technology solutions for global clinical trials. Trialbee – Dedicated to patients; driven by science; and powered by data. For more information, visit trialbee.com and contact us at firstname.lastname@example.org.
Crossroads B2B for Trialbee
+1 (001) 919.270.8054